Literature DB >> 31785092

GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies.

Georg Leubolt1, Enric Redondo Monte1, Philipp A Greif1.   

Abstract

The GATA family of transcription factors are zinc finger (ZF) DNA-binding proteins that regulate transcription during development and cell differentiation. GATA2 plays an essential role in the regulation of hematopoiesis. As a result, mutations in this gene or alterations in its expression level or function have been linked to a variety of human hematologic disorders. In this review, we summarize the findings and developments over the recent years regarding the clinical correlations and functional properties of distinct GATA2 mutations in hematopoietic malignancies, with particular focus on the mutational hotspots in the ZF domains.
© 2019 The Authors. IUBMB Life published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  GATA2; genetics; leukemia; myeloid malignancy; transcription factors

Mesh:

Substances:

Year:  2019        PMID: 31785092     DOI: 10.1002/iub.2204

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  3 in total

Review 1.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 2.  GATA 2 Deficiency: Focus on Immune System Impairment.

Authors:  Francesco Fabozzi; Angela Mastronuzzi; Giulia Ceglie; Riccardo Masetti; Davide Leardini
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

3.  Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.

Authors:  Roger Mulet-Lazaro; Stanley van Herk; Claudia Erpelinck; Eric Bindels; Mathijs A Sanders; Carlo Vermeulen; Ivo Renkens; Peter Valk; Ari M Melnick; Jeroen de Ridder; Michael Rehli; Claudia Gebhard; Ruud Delwel; Bas J Wouters
Journal:  Blood       Date:  2021-07-15       Impact factor: 25.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.